Patents by Inventor Ian Slaymaker

Ian Slaymaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
    Patent number: 12767959
    Abstract: The invention features nucleobase editors and multi-effector nucleobase editors having an improved editing profile with minimal off-target deamination, compositions comprising such editors, and methods of using the same to generate modifications in target nucleobase sequences.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 20, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Yi Yu, Ian Slaymaker, Jason Michael Gehrke, Seung-Joo Lee, David A. Born
  • MODIFIED CAS9-IID NUCLEASES AND USES THEREOF
    Publication number: 20260317759
    Abstract: Described herein are systems, methods, and compositions capable of targeting nucleic acids. Describe in certain exemplary embodiments herein are a class of small Cas proteins (Type II-D Cas proteins) and systems thereof. Also described in certain exemplary embodiments herein are methods of modifying target sequences using the class of small Cas proteins (Type II-D Cas proteins) and systems thereof described herein.
    Type: Application
    Filed: May 3, 2024
    Publication date: October 15, 2026
    Applicant: AERA THERAPEUTICS, INC.
    Inventors: Alexander THOMAS, Neena PYZOCHA, Hannah KEMPTON, Liyang ZHANG, Yuanyuan GAO, Ming SUN, Sean BENLER, Ian SLAYMAKER
  • SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
    Publication number: 20260317742
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the present disclosure provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
    Type: Application
    Filed: May 14, 2026
    Publication date: October 15, 2026
    Inventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Ian Slaymaker
  • CAS12B enzymes and systems
    Patent number: 12753406
    Abstract: Described herein are systems, methods, and compositions for targeting nucleic acids. In certain example embodiments, non-naturally occurring or engineered RNA-targeting systems contain an RNA-targeting Cas12b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: October 6, 2026
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Feng Zhang, Jonathan Strecker, Ian Slaymaker, Sara Jones
  • MODIFIED ISCB NUCLEASES, MODIFIED GUIDE RNAS, AND USES THEREOF
    Publication number: 20260286324
    Abstract: Disclosed herein are novel polypeptides having nuclease activity. The polypeptides can effect modifications at defined locations within target nucleic acids, e.g., DNA and RNA. Also disclosed herein modified guide RNAs. The polypeptides and guide RNAs are useful in compositions, systems and methods, to make site specific alterations of target nucleic acid sequences.
    Type: Application
    Filed: March 29, 2024
    Publication date: September 24, 2026
    Applicant: AERA THERAPEUTICS, INC.
    Inventors: Liyang ZHANG, Max Atticus ENGLISH, Colin McGAW, Hannah KEMPTON, Sean BENLER, Ian SLAYMAKER
  • COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY
    Publication number: 20260256848
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with alpha-1 anti-trypsin (A1AT) deficiency. In particular embodiments, the invention provides methods for correcting mutations in an A1AT polynucleotide using an adenosine deaminase base editor, ABE8, having unprecedented levels of efficiency.
    Type: Application
    Filed: February 6, 2026
    Publication date: September 3, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Bernd ZETSCHE, Ian SLAYMAKER, Yi YU, David A. BORN, Seung-Joo LEE
  • NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS
    Publication number: 20260209746
    Abstract: The invention features base editors having reduced non-target deamination, methods of using the base editors, and assays for characterizing base editors as having decreased non-target deamination, e.g. compared to programmed, on-target deamination.
    Type: Application
    Filed: November 20, 2025
    Publication date: July 23, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Jason Michael Gehrke, Nicole Gaudelli, Yi Yu
  • MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE
    Publication number: 20260176635
    Abstract: The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
    Type: Application
    Filed: February 27, 2026
    Publication date: June 25, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, David A. BORN, Seung-Joo LEE, Jason M. GEHRKE
  • Systems, methods, and compositions for targeted nucleic acid editing
    Patent number: 12655403
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the present disclosure provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 16, 2026
    Inventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Ian Slaymaker
  • CRISPR enzymes and systems
    Patent number: 12644111
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
    Type: Grant
    Filed: December 2, 2024
    Date of Patent: June 2, 2026
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Ian Slaymaker, Soumya Kannan, Jonathan Gootenberg, Omar Abudayyeh
  • Compositions and methods for treating alpha-1 antitrypsin deficiency
    Patent number: 12622931
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with alpha-1 anti-trypsin (A1AT) deficiency. In particular embodiments, the invention provides methods for correcting mutations in an A1AT polynucleotide using an adenosine deaminase base editor. ABE8, having unprecedented levels of efficiency.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: May 12, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Bernd Zetsche, Ian Slaymaker, Yi Yu, David A. Born, Seung-Joo Lee
  • Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
    Patent number: 12612618
    Abstract: The invention features base editors having reduced non-target deamination, methods of using the base editors, and assays for characterizing base editors as having decreased non-target deamination, e.g. compared to programmed, on-target deamination.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 28, 2026
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Jason Michael Gehrke, Nicole Gaudelli, Yi Yu
  • COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
    Publication number: 20260108590
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Application
    Filed: October 29, 2025
    Publication date: April 23, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
    Patent number: 12600971
    Abstract: The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 14, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Ian Slaymaker, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Jason M. Gehrke
  • CRISPR ENZYMES AND SYSTEMS WITH MODIFIED PAM SPECIFICITY
    Publication number: 20260071198
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Aspects of the invention in particular relate to Cpf1 mutants having altered PAM specificity.
    Type: Application
    Filed: July 8, 2025
    Publication date: March 12, 2026
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Feng Zhang, Bernd Zetsche, Linyi Gao, Ian Slaymaker, David Benjamin Turitz Cox
  • COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
    Publication number: 20260061041
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Application
    Filed: November 14, 2025
    Publication date: March 5, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • CRISPR enzymes and systems
    Patent number: 12410468
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: September 9, 2025
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTUITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEAGE
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • CRISPR enzymes and systems with modified pam specificity
    Patent number: 12410416
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Aspects of the invention in particular relate to Cpf1 mutants having altered PAM specificity.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: September 9, 2025
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Bernd Zetsche, Linyi Gao, Ian Slaymaker, David Benjamin Turitz Cox
  • CRISPR ENZYMES AND SYSTEMS
    Publication number: 20250250618
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Application
    Filed: January 17, 2025
    Publication date: August 7, 2025
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • CRISPR ENZYMES AND SYSTEMS
    Publication number: 20250250617
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Application
    Filed: January 17, 2025
    Publication date: August 7, 2025
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker